SCHEMBL9299549

SCHEMBL9299549

Ic1nc[nH]n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2010079 0.65
SCHEMBL11511420 0.63
SCHEMBL10531111 0.62
SCHEMBL11424279 0.62
Amitrole SCHEMBL788110 0.62 HSP90AA1 (0.33)
SCHEMBL16673433 0.62
SCHEMBL8953661 0.62
SCHEMBL1006446 0.62
SCHEMBL13218335 0.62
SCHEMBL62313 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224262-A1 COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR MONTE ROSA THERAPEUTICS AG (CH) 2025-10-30 WO disclosed
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 EP disclosed
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2025-08-21 US disclosed
WO-2024092039-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2024-05-02 WO disclosed
WO-2023023664-A1 SULFONYL-TRIAZOLES USEFUL AS COVALENT KINASE LIGANDS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2023-02-23 WO disclosed
WO-2023023376-A2 SULFONYL-TRIAZOLES USEFUL AS COVALENT KINASE LIGANDS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2023-02-23 WO disclosed
US-20220402904-A1 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof NOVARTIS AG (CH) 2022-12-22 US disclosed
US-11225481-B2 Xanthine derivative inhibitors of BET proteins CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-01-18 US disclosed
US-11021501-B2 Creatine phosphate analog prodrugs, compositions and methods of use thereof Farmington Pharma Development (US) 2021-06-01 US disclosed
EP-3253755-B1 NOVEL CYCLOPROPABENZOFURANYL PYRIDOPYRAZINEDIONES PFIZER (US) 2020-08-26 EP disclosed
WO-2013107820-A1 NOVEL FAP INHIBITORS UNIVERSITEIT ANTWERPEN (BE) 2013-07-25 WO disclosed
CN-101189744-B Porous semiconductor layer formation material, semiconductor element and its manufacture method, electronic device and electronic device SEIKO EPSON CORP 2012-05-30 CN disclosed
WO-2011059839-A1 BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2011-05-19 WO disclosed
WO-2010088574-A1 AZABENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-08-05 WO disclosed
WO-2010077947-A1 PHTHALAZINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-07-08 WO disclosed
WO-2010077686-A1 ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-07-08 WO disclosed
EP-2033952-A1 Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity Shionogi&Co., Ltd. (JP) 2009-03-11 EP disclosed
CN-101189744-A Porous semiconductor layer formation material SEIKO EPSON CORP (JP) 2008-05-28 CN disclosed
CN-101080951-A Composition for conductive material, conductive layer, electronic device, and electronic apparatus SEIKO EPSON CORP (JP) 2007-11-28 CN disclosed
US-5328803-A Alkali developable solutions with carboxy group binders and monomer with initiators FUJI PHOTO FILM CO., LTD. (JP) 1994-07-12 US disclosed